Figure 6: slanDCs in breast cancer TDLN.
From: slanDCs selectively accumulate in carcinoma-draining lymph nodes and marginate metastatic cells
(a) Graph illustrates the frequency of slanDCs in non-sentinel M-TDLN from the entire cohort (NSLN; n=80), metastatic breast cancer SLN (M-SLN; n=51) and non-metastatic breast cancer SLN (NM-SLN; n=22). (b) Graph illustrates the frequency of slanDCs in M-SLN with (ALND+) or without (ALND−) metastasis in the ALND (***P<0.0001; P>0.05 is nonsignificant (NS) by Fisher’s test). (c–f) Sections are from a representative M-SLN and matched ALND as indicated, and stained for DD2 (c,e) and H&E (d,f). T, tumour. Sections are counterstained with Meyer’s haematoxylin (c,e). Original magnifications: 200X (c,e, scale bar,100 μm) and 100X (d,f, scale bar, 200 μm).
